From DEEP SCIENTIFIC Innovations to Pronounced Medical Breakthroughs
From DEEP SCIENTIFIC Innovations to Pronounced Medical Breakthroughs

Based in Boston, Genosco is a clinical stage biotech specializing in

the discovery and development of novel kinase inhibitors for

patients with unmet medical needs

Based in Boston, Genosco is a clinical stage

biotech specializing in the discovery and development

of novel kinase inhibitors for patients with unmet

medical needs

  • 01.
    Experienced
    Team

    Dedicated team of experts in
    kinase targeted therapies

  • 02.
    Proprietary
    Discovery
    Platform

    GENO-KTM/GENO-DTM platform enables us to identify rare sequences and rapidly generate highly selective compounds

  • 03.
    Strong and
    Diverse
    Pipeline

    Multiple independent and
    partnered pipelines

  • 04.
    Proven Track
    Record

    Backed by proven R&D through global out-licensing partnership

  • 01.
    Experienced
    Team

    Dedicated team of experts in
    kinase targeted therapies

  • 02.
    Proprietary
    Discovery
    Platform

    GENO-KTM/GENO-DTM platform enables us to identify rare sequences and rapidly generate highly selective compounds

  • 03.
    Strong and
    Diverse
    Pipeline

    Multiple independent and
    partnered pipelines

  • 04.
    Proven Track
    Record

    Backed by proven R&D through global out-licensing partnership

GENO-K™/GENO-D™ Platform
GENO-K™
  • Protein
    Database

  • Ligand
    Library

  • Rare Sequence
    Targeting

GENO-D™
  • Protein Degrader
    Library

  • Degrader Screening
    Technology

  • Degrader Design
    Technology

EGFR
Lazertinib
Development Program
  • Non-Small Cell Lung Cancer (NSCLC)
SYK
SYK Inhibitor (Cevidoplenib)
Development Programs
  • Immune Thrombocytopenia (ITP)
ROCK2
ROCK2 Inhibitor
Development Program
  • Idiopathic Pulmonary Fibrosis (IPF)
  • Cerebral Cavernous Malformation (CCM)
MGD
TPD/MGD
Development Program
  • MYC-driven cancer
We are unified under the shared vision to improve patients’ quality of life tomorrow, together.
To achieve this, it is important to focus on strengthening the discovery platform based on cutting-edge science,
and to create an open and positive working environment where employees can unleash their full creativity.
John Koh, CEO of Genosco
Press Release
  • Mar 26, 2025

    [BioTalkTalk] Interview with Dr. John (Jongsung) Koh, Key Developer of Leclaza at Genosco

  • Aug 20, 2024

    Lazertinib With Amivantamab Approved by FDA for Use in NSCLC